Nektar Therapeutics buy HC Wainwright
Start price
10.12.24
/
50%
€0.96
Target price
10.12.25
€6.18
Performance (%)
-39.01%
End price
11.12.25
-
Summary
This prediction is currently being closed. Massive losses of -39.01% have been the result for the BUY prediction by HC_Wainwright. HC_Wainwright has a follow-up prediction for Nektar Therapeutics where he still thinks Nektar Therapeutics is a Buy. HC_Wainwright has 50% into this predictionNektar is a clinical-stage biopharmaceutical company focused on developing treatments for cancer, autoimmune diseases, and chronic pain. The company's pipeline includes product candidates based on its proprietary drug delivery technology, which improves the delivery and effectiveness of drugs in the body. Some of its most advanced candidates include NKTR-214, a cancer immunotherapy, and NKTR-181, a non-opioid pain medication. Nektar is listed on the NASDAQ exchange under the ticker symbol NKTR.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Nektar Therapeutics | - | - | - |
| iShares Core DAX® | 1.644% | 4.865% | 25.089% |
| iShares Nasdaq 100 | 0.747% | 2.923% | 8.975% |
| iShares Nikkei 225® | 2.442% | 6.212% | 21.408% |
| iShares S&P 500 | 0.618% | 2.843% | 5.726% |
Comments by HC_Wainwright for this prediction
In the thread Discuss Nektar Therapeutics
Nektar Therapeutics (NASDAQ: NKTR) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $6.50 price target on the stock.
Ratings data for NKTR provided by MarketBeat
In the thread Trading Nektar Therapeutics
Die von HC_Wainwright gewählte maximale Laufzeit wurde überschritten
Current prediction by HC_Wainwright for Nektar Therapeutics
Nektar Therapeutics
Start price
Target price
Perf. (%)
€0.80
25.02.25
25.02.25
€6.19
25.02.26
25.02.26
-27.14%
06.06.25
06.06.25
Stopped prediction by HC_Wainwright for Nektar Therapeutics
Nektar Therapeutics
Start price
Target price
Perf. (%)
€0.78
13.03.25
13.03.25
€5.97
13.03.26
13.03.26
-25.18%
06.06.25
06.06.25